Systematic Review of TST Responses in People Living with HIV in Under-Resourced Settings: Implications for Isoniazid Preventive Therapy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Kerkhoff, Andrew D ^a,b   Kranzer, Katharina ^b,c   Samandari, Taraz ^d   Nakiyingi Miiro, Jessica ^e   Whalen, Christopher C ^f   Harries, Anthony D ^c,g   Lawn, Stephen D ^b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f UNIVERSITY OF GEORGIA   (United States)

^g INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

AFRICA; ARTICLE; ASIA; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; GENETIC HETEROGENEITY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; OUTCOME ASSESSMENT; PREVALENCE; SYSTEMATIC REVIEW; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; ISONIAZID; PREVALENCE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84870261812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049928     Document Type: Article

References (61)

1. Lawn SD, Zumla AI, (2011) Tuberculosis. Lancet 378: 57-72.
2. World Health Organization (2011) Global tuberculosis control 2011. Available: http://www.who.int/tb/publications/global_report/en/index.html. Accessed 2011 Dec 21.
3. World Health Organization (2010) The Global Plan to STOP TB 2011-2015. World Health Organization, Geneva.
4. Lawn SD, Kranzer K, Wood R, (2009) Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-Limited Settings. Clin Chest Med 30: 685-99.
5. World Health Organization (2008) WHO three I's meeting. Report of a joint WHO HIV/AIDS and TB Department Meeting. WHO, Geneva. Available: http://www.who.int/hiv/pub/meetingreports/WHO_3Is_meeting_report.pdf.
6. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, et al. (2010) The HIV-associated tuberculosis epidemic-when will we act? Lancet 375: 1906-19.
7. World Health Organization (2010) Global tuberculosis control 2010. Geneva: World Health Organization. Available: http://www.who.int/tb/publications/global_report/2010/en/index.html.
8. Akolo C, Adetifa I, Shepperd S, Volmink J (2010) Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD000171. DOI: 10.1002/14651858.CD000171.pub3.
9. World Health Organization (1998) Policy statement on preventive therapy against tuberculosis in people living with HIV.WHO/TB/98.255 UNAIDS/98.34. Available: http://whqlibdoc.who.int/hq/1998/WHO_TB_98.255.pdf.
10. World Health Organization (2011) Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization, Geneva, Switzerland. Available: http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf. Accessed 2011 Jan 30.
11. Wood R, Liang H, Wu H, Middelkoop K, Oni T, et al. (2010) Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis 14: 406-12.
12. Lawn SD, Butera ST, Shinnick TM, (2002) Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect 4: 635-46.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
14. Lawn SD, Churchyard G, (2009) Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 4: 325-33.
15. World Bank website. (2011) Available: http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
16. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-58.
17. Mugisha B, Bock N, Mermin J, Odeke RM, Miller B, et al. (2006) Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis 10: 761-7.
18. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, et al. (2012) Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12: 45-55.
19. Shrestha RK, Mugisha B, Bunnell R, Mermin J, Odeke R, et al. (2007) Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis 11: 747-54.
20. Hausler HP, Sinanovic E, Kumaranayake L, Naidoo P, Schoeman H, et al. (2006) Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 84: 528-36.
21. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. (2011) 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 377: 1588-98.
22. Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, et al. (2012) TB incidence increase after cessation of 36 months isoniazid prophylaxis in HIV+ adults in Botswana. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA. Abstract #147.
23. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, et al. (2011) New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 365: 11-20.
24. Smith T, Samandari T, Abimola T, Marston B, Sangrujee N, (2011) Cost-effectiveness of alternative policies to reduce TB disease and death in HIV-infected persons in Botswana. Am J Respir Crit Care Med 183: A5310.
25. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD, (2006) Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 12: 744-51.
26. Centers for Disease Control and Prevention (2010) Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection- United States, 2004-2008. MMWR Morb Mortal Wkly Rep 59: 224-9.
27. Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, et al. (2010) Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in Botswana. Am J Respir Crit Care Med 182: 278-85.
28. Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, et al. (2010) Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 24Suppl 5: S29-S36.
29. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett P, et al. (2007) Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. PLoS Med 4: e22.
30. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, et al. (2001) Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 15: 215-22.
31. Rodriguez JI, Arias M, Paris SC, Arbelaez MP, Betancur J, et al. (1997) Tuberculin skin test and CD4+/CD8+ T cell counts in adults infected with the human immunodeficiency virus in Medellin, Colombia. Mem Inst Oswaldo Cruz 92: 245-50.
32. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, et al. (1997) Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 11: 875-82.
33. Pistone T, Kony S, Faye-Niang MA, Ndour CT, Gueye PM, et al. (2002) A simple clinical and paraclinical score predictive of CD4 cells counts below 400/mm3 in HIV-infected adults in Dakar University Hospital, Senegal. Trans R Soc Trop Med Hyg 96: 167-72.
34. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. (2007) The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21: 1441-8.
35. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, et al. (2010) Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 10: 489-98.
36. Kerkhoff AD, Wood R, Lawn SD, (2011) Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis? AIDS 25: 1003-6.
37. Suthar AB, Lawn SD, Del Amo J, Getahun H, Dye C, et al. (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9: e1001270.
38. Lawn SD, Myer L, Bekker LG, Wood R, (2006) Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20: 1605-12.
39. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD, (2012) Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community. PLoS One 7: e34156.
40. Rangaka MX, Boulle A, Wilkinson RJ, van Cutsem G, Cohen K, et al. (2012) Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy. Programme and Abstracts of the XIX International AIDS Conference. International AIDS Society. Washington DC, USA. Abstract THLBB03.
41. Girardi E, Palmieri F, Zaccarelli M, Tozzi V, Trotta MP, et al. (2002) High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. AIDS 16: 1976-9.
42. Lawn SD, Bekker LG, Wood R, (2005) How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 19: 1113-24.
43. Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A, (2011) Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 204Suppl 4: S1168-S1178.
44. Lugada ES, Watera C, Nakiyingi J, Elliott A, Brink A, et al. (2002) Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda. Int J Tuberc Lung Dis 6: 326-31.
45. Rangaka MX, Wilkinson KA, Seldon R, Van CG, Meintjes GA, et al. (2007) Effect of HIV-1 Infection on T-Cell-based and Skin Test Detection of Tuberculosis Infection. Am J Respir Crit Care Med 175: 514-20.
46. Karam F, Mbow F, Fletcher H, Senghor CS, Coulibaly KD, et al. (2008) Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS One 3: e1441.
47. Oni T, Burke R, Tsekela R, Bangani N, Seldon R, et al. (2011) High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 66: 669-73.
48. Garcia-Garcia ML, Valdespino-Gomez JL, Garcia-Sancho C, Mayar-Maya ME, Palacios-Martinez M, et al. (2000) Underestimation of Mycobacterium tuberculosis infection in HIV-infected subjects using reactivity to tuberculin and anergy panel. Int J Epidemiol 29: 369-75.
49. Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, et al. (2007) Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2: e826.
50. Balcells ME, Perez CM, Chanqueo L, Lasso M, Villanueva M, et al. (2008) A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis 12: 645-52.
51. Moura LC, Ximenes RA, Ramos HL, Miranda Filho DB, Freitas CD, et al. (2011) An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS. BMC Public Health 11: 687.
52. Davarpanah MA, Rasti M, Mehrabani SS, Allahyari R, Neirami R, et al. (2009) Association between PPD and QuantiFERON Gold TB test in TB infection and disease among HIV-infected individuals in southern Iran. Iranian Red Crescent Med J 11: 71-75.
53. Alavi SM, Nadimi M, Shokri S, Zamani GA, (2010) Latent tuberculosis infection in individuals with human immunodeficiency virus infection: comparison of tuberculin skin test to the anti TB-IgM antibodies.Pakistan J Med Sci. 26: 11-14.
54. Mardani M, Tabarsi P, Mohammadtaheri Z, Chitsaz E, Farokhzad B, et al. (2010) Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran. Ann Thorac Med 5: 43-6.
55. Vitek E, Gusseinova N, Laricheva N, Vasiliev S, Molotilov V, et al. (2009) Factors associated with positive tuberculin skin test results among HIV-infected persons in Orel Oblast, Russia. Int J Tuberc Lung Dis 13: 829-35.
56. Yanai H, Uthaivoravit W, Mastro TD, Limpakarnjanarat K, Sawanpanyalert P, et al. (1997) Utility of tuberculin and anergy skin testing in predicting tuberculosis infection in human immunodeficiency virus-infected persons in Thailand. Int J Tuberc Lung Dis 1: 427-34.
57. Hiransuthikul N, Hanvanich M, Dore GJ, Mokkhawes T, Li Y, et al. (2003) Factors associated with tuberculin skin test reactivity among HIV-infected people in Bangkok. Southeast Asian J Trop Med Public Health 34: 804-9.
58. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, et al. (2007) Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis 45: 241-9.
59. Swaminathan S, Subbaraman R, Venkatesan P, Subramanyam S, Kumar SR, et al. (2008) Tuberculin skin test results in HIV-infected patients in India: implications for latent tuberculosis treatment. Int J Tuberc Lung Dis 12: 168-73.
60. Jiang W, Shao L, Zhang Y, Zhang S, Meng C, et al. (2009) High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area. BMC Immunol 10: 31.
61. Nguyen DT, Hung NQ, Giang LT, Dung NH, Lan NT, et al. (2011) Improving the diagnosis of pulmonary tuberculosis in HIV-infected individuals in Ho Chi Minh City, Viet Nam. Int J Tuberc Lung Dis 15: 1528-34, i.